Acceptance of New Drug Application for Suprachoroidal Use of Arcatus® in Australia

Clearside Biomedical's Asia-Pacific partner, Arctic Vision, has announced that its new drug application for the suprachoroidal use of Arcatus® in treating Uveitic Macular Edema has been accepted in Australia. This exciting development comes as Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®..